A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. Privately held City Therapeutics is getting $46 million in the deal. That ...

The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) submitted by Soleno ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) ...

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity ...

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Please see the full Prescribing Information, including Medication Guide. About Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the ...

Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...